Navigation Links
BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
Date:7/29/2008

High Performance Monte Carlo Algorithm Generates Precise Dose Calculations

Within Seconds

WESTCHESTER, Ill., July 29 /PRNewswire/ -- BrainLAB, a leader in software-driven systems for targeted, less-invasive medical treatments, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Monte Carlo Dose Calculation Algorithm, which is already being used at several clinical cooperation sites worldwide.

In the past, clinicians had limited treatment choices or have been unable to include Monte Carlo method calculations into their routine for dose calculation due to numerous factors such as the extreme amount of time needed, restrictions of treatment planning software to a single machine or treatment modality and its integration into available software. Although the Monte Carlo algorithm is widely accepted as the gold standard for calculation in treatment planning accuracy, the aforementioned limitations have inhibited its clinical implementation. To offer superior treatment possibilities for patients and tools that seamlessly integrate into the clinical workflow, BrainLAB has developed new Monte Carlo Dose Calculation software that makes high-precision treatment available in everyday clinical practice.

The BrainLAB Monte Carlo Dose Calculation software is a high performance Monte Carlo algorithm for therapeutic photon beams supporting nearly all linear accelerator and multi-leaf collimator (MLC) types. Monte Carlo is now available as an option on the iPlan(R) RT Dose treatment planning software. Dose calculations can be completed within seconds for conformal beam and dynamic arc treatments and within a few minutes for complex IMRT cases.

"The new BrainLAB Monte Carlo algorithm integrates some of the most advanced image registration and segmentation tools available in the clinical environment, providing a powerful tool to tackle the most challenging radiosurgery cases in lung and
'/>"/>

SOURCE BrainLAB Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
2. Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS)
3. National Brain Tumor Foundation Unites with BrainLAB in Support of Patient Education
4. Align Technology Announces Second Quarter Fiscal 2008 Results
5. Monogram Announces 2008 Second Quarter Financial Results
6. Webcast Alert: Medial Saude S/A Announces Second Quarter 2008 Earnings Conference Call Webcast
7. The Quantum Group Announces Exclusive Screening of New PWeR(TM) System
8. Burgess Announces Expanded Software Partnership With Health Net
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Fast Radios Announces Publication of Two Way Radio Guide for Commercial Customers
11. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)... November is Alzheimer,s Awa...eimer Report declares that more than 35 million pe...nior Living Communities , an industry innovator wi...Alzheimer,s/memory care communities in Wisconsin a...o care for people with Alzheimer,s. , ...
(Date:11/10/2009)...TLANTA Emory University Rollins School of Public ... of topics at the American Public Health Associati...tudy that examined compliance with national recomm...nts within 10 minutes of their arrival to the Emer...h research findings from Emory scientists are high...
(Date:11/9/2009)..., Campaign Backed by USDA Secretary Vilsack, Gov..., BOSTON, Nov. 9 In a ...an James P. McGovern (D-Worcester) called for all ... helping hungry patients in their care. ,, "Wi...re," said McGovern at today,s press conference at ...
(Date:11/9/2009)..., SHENZHEN, China, Nov. 9 /PRNewswire-Asia-Fi...(NYSE: MR ), a leading developer, manufacturer an... today its selected unaudited,financial results fo...r 30,2009. , , Highlights for Operations as o... revenues were $151.1 million, an increase of, ...
(Date:11/9/2009)..., SBA Provision, Antitrust Language, Federal Tra...Senate ,, WASHINGTON, Nov. 9 /PRNewswire-USNew...le Health Care for America Act (H.R. 3962) allowin... by health insurance exchanges is positive, but ot...ccording to the National Association of Profession...
Breaking Medicine News(10 mins):Health News:Top 10 Tips for Alzheimer's Caregivers 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 3Health News:Mindray Announces Third Quarter 2009 Financial Results 2Health News:Mindray Announces Third Quarter 2009 Financial Results 3Health News:Mindray Announces Third Quarter 2009 Financial Results 4Health News:Mindray Announces Third Quarter 2009 Financial Results 5Health News:Mindray Announces Third Quarter 2009 Financial Results 6Health News:Mindray Announces Third Quarter 2009 Financial Results 7Health News:Mindray Announces Third Quarter 2009 Financial Results 8Health News:Mindray Announces Third Quarter 2009 Financial Results 9Health News:Mindray Announces Third Quarter 2009 Financial Results 10Health News:Mindray Announces Third Quarter 2009 Financial Results 11Health News:Mindray Announces Third Quarter 2009 Financial Results 12Health News:Mindray Announces Third Quarter 2009 Financial Results 13Health News:Mindray Announces Third Quarter 2009 Financial Results 14Health News:Mindray Announces Third Quarter 2009 Financial Results 15Health News:Mindray Announces Third Quarter 2009 Financial Results 16Health News:Mindray Announces Third Quarter 2009 Financial Results 17Health News:Mindray Announces Third Quarter 2009 Financial Results 18Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 2Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 3
...Two carotid stenting,trials examining outcomes in ...e results that are comparable to guidelines establ...or patients treated with carotid artery,surgery. T...anscatheter Cardiovascular Therapeutics (TCT),scie...
...bar with innovative CM-X gives new meaning to diab...TO, Oct. 23 Heart Chocolate(TM) with CM-X(TM),rec...tion (ILS), is more,than just another so-called di...consumers are left feeling unsatisfied,because alt...
...to Provide Information and Product Acquisition, S... of,the recent tragedies caused by Community Acqui...ions, LLC, part of the Key Medical Group of,Compan...o combat and kill these superbugs. The website:, h...
...,s plasma, rare lung condition, study finds , TUES...ted by females may not be as dangerous as believed...e that would limit the use of plasma from female d...rtion of blood that,s separated from red blood cel...
...dies presented at the AACR-NCI-EORTC International...eutics demonstrate the flexibility of targeted the...and tested in human trials more quickly and safely...rs, both currently involved in solid tumor clinica...
...outhfield, MI October 23, 2007 The Juvenile Diab...itable funder of type 1 diabetes research, today a...Research Laboratories (HPRL) to support the compan...are thrilled to be partnering with Housey Pharmace...
Other Medicine News:Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 2Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 3Health News:Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery 4Health News:Heart Chocolate(TM) With CM-X(TM) is Loved by Chocolate Connoisseurs and Diabetics Alike 2Health News:Heart Chocolate(TM) With CM-X(TM) is Loved by Chocolate Connoisseurs and Diabetics Alike 3Health News:Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not 2Health News:Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not 3Health News:Female Blood Donor Concern May Be Unfounded 2Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 2Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 3Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 4Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 5Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 6Health News:Clinical studies in the pipeline: the therapies of tomorrow in trials today 7Health News:JDRF partners with Housey Pharmaceutical Research Laboratories 2
(Date:11/9/2009)...h., Nov. 9 Cardiac Sci...er in automated external defibrillator ( AED ) a...nounced revenue of $38.9 million for the third qua...evious guidance. The Company also recorded a charg... and a non-cash charge of $44.0 million to increas...
(Date:11/9/2009)...l., Nov. 9 Landauer, In... and environmental radiation monitoring services, ... in accordance with its long-term strategic priori...itions of Global Physics Solutions, Inc. (GPS) and..., President and CEO of Landauer. "These acquisitio...
(Date:11/9/2009)...v. 9 Keryx Biopharmaceut...company focused on the acquisition, development an...eutical products for the treatment of life-threate...(the "Company"), today announced its results for t...t September 30, 2009, the Company had cash, cash e...
Breaking Medicine Technology:Cardiac Science Announces Third Quarter Results 2Cardiac Science Announces Third Quarter Results 3Cardiac Science Announces Third Quarter Results 4Cardiac Science Announces Third Quarter Results 5Cardiac Science Announces Third Quarter Results 6Cardiac Science Announces Third Quarter Results 7Cardiac Science Announces Third Quarter Results 8Cardiac Science Announces Third Quarter Results 9Cardiac Science Announces Third Quarter Results 10Cardiac Science Announces Third Quarter Results 11Cardiac Science Announces Third Quarter Results 12Cardiac Science Announces Third Quarter Results 13Cardiac Science Announces Third Quarter Results 14Cardiac Science Announces Third Quarter Results 15Cardiac Science Announces Third Quarter Results 16Cardiac Science Announces Third Quarter Results 17Cardiac Science Announces Third Quarter Results 18Cardiac Science Announces Third Quarter Results 19Cardiac Science Announces Third Quarter Results 20Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 2Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 3Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 4Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 6Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 1Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 2Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 3Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 1Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 6Irvine Scientific and Selexis to Announce Results of Successful Collaboration 14427 1Irvine Scientific and Selexis to Announce Results of Successful Collaboration 14427 2
...w Aggrastat Study in American Heart Journal , ,WI...TSX:MPH;,Amex:MCU), a cardiovascular focused, biop...o-year, follow-up results from the,STRATEGY (Singl...Stent Versus Abciximab and Bare Metal Stent In Acu...the July edition of the Journal,of the American Co...
...n., July 11, 2007 /PRNewswire/ -- Phase 3 results,...l dabigatran,etexilate once daily, administered fo...parin, also administered for an average of 33,days...ll-cause,mortality after total hip replacement sur...sociated with dabigatran etexilate was,similar to ...
Other Medicine Technology:Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 2Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 3Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 4Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 5Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5
... doors, 8 shelves. Over-sized compressor. Tripl...scent interior lighting. Self-Contained System No... Full One Year Warranty on Parts & Labor and an Ad...ilable as a chromatography unit which includes two...
... door 4 shelves. Over-sized compressor. Triple ...ent interior lighting. Self-Contained System No p...ull One Year Warranty on Parts & Labor and an Addi...able as a chromatography unit which includes two a...
Flammable Chemical Storage Cabinets, Justrite Model J25452
Flammable Chemical Storage Cabinets
Medicine Products: